Lipocine Earnings Estimate

LPCN -  USA Stock  

USD 1.12  0.05  4.67%

Many public companies, such as Lipocine, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Lipocine's earnings estimates, investors can diagnose different trends across Lipocine's analyst sentiment over time as well as compare current estimates against different timeframes.
Lipocine is projected to generate -0.18 in earnings per share on the 31st of December 2021. Lipocine earnings estimates module stress-tests analyst consensus about projected Lipocine EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Additionally, see Stocks Correlation.

Lipocine Earnings Estimates 

Gross Profit is expected to rise to about 152.4 K this year, although the value of Profit Margin will most likely fall to (72.82) .

Lipocine Earnings Estimation Breakdown

Calculation of earning per share of Lipocine is based on official Zacks consensus of 2 analysts regarding Lipocine future annual earnings. Given the historical accuracy of 47.02%, the future earnings per share of Lipocine is estimated to be -0.18 with the lowest and highest values of -0.23 and -0.12, respectively. Please note that this consensus of annual earnings estimates for Lipocine is an estimate of EPS before non-recurring items and including employee stock options expenses
Current EPS
7th of December 2021
Estimated EPS

Lipocine Earnings Projection Consensus

Suppose the current estimates of Lipocine's value are higher than the current market price of the Lipocine stock. In this case, investors may conclude that Lipocine is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Lipocine's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyCurrent EPSEPS Estimate for 31st of December 2021





Lipocine Earnings per Share Projection vs Actual

Actual Earning per Share of Lipocine refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Lipocine predict the company's earnings will be in the future. The higher the earnings per share of Lipocine, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Lipocine Estimated Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Lipocine, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Lipocine should always be considered in relation to other companies to make a more educated investment decision.

Lipocine Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Lipocine's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS

About Lipocine Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Lipocine earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Lipocine estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Lipocine fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2021
Accumulated Retained Earnings Deficit-172 M-176.6 M
Earning Before Interest and Taxes EBIT-20.6 M-22.2 M
Earnings per Basic Share(0.38) (0.41) 
Earnings per Diluted Share(0.38) (0.41) 
Price to Earnings Ratio(3.58) (3.86) 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-20.6 M-22.2 M
Earnings before Tax-21 M-21.5 M
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The companys pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Lipocine without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Suggestion Now


Portfolio Suggestion

Get suggestions outside of your existing asset allocation including your own model portfolios
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Lipocine using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Lipocine information on this page should be used as a complementary analysis to other Lipocine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Complementary Tools for Lipocine Stock analysis

When running Lipocine price analysis, check to measure Lipocine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipocine is operating at the current time. Most of Lipocine's value examination focuses on studying past and present price action to predict the probability of Lipocine's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lipocine's price. Additionally, you may evaluate how the addition of Lipocine to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
CEO Directory
Screen CEOs from public companies around the world
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Is Lipocine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine Lipocine value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.